Context Therapeutics Management
Management criteria checks 3/4
Context Therapeutics' CEO is Martin Lehr, appointed in Jan 2015, has a tenure of 9.92 years. total yearly compensation is $860.68K, comprised of 57.1% salary and 42.9% bonuses, including company stock and options. directly owns 1.31% of the company’s shares, worth $1.49M. The average tenure of the management team and the board of directors is 3.1 years and 3.8 years respectively.
Key information
Martin Lehr
Chief executive officer
US$860.7k
Total compensation
| CEO salary percentage | 57.1% |
| CEO tenure | 9.9yrs |
| CEO ownership | 1.3% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Aug 15
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$30m |
| Jun 30 2024 | n/a | n/a | -US$19m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$861k | US$492k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$21m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$1m | US$477k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$2m | US$291k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$648k |
| Dec 31 2020 | US$250k | US$250k | US$1m |
| Dec 31 2019 | US$250k | US$250k | -US$6m |
Compensation vs Market: Martin's total compensation ($USD860.68K) is above average for companies of similar size in the US market ($USD642.50K).
Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.
CEO
Martin Lehr (40 yo)
9.9yrs
Tenure
US$860,681
Compensation
Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. Mr. Lehr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.9yrs | US$860.68k | 1.31% $ 1.5m | |
| CFO & Treasurer | 3.1yrs | US$606.68k | 0.053% $ 60.8k | |
| Chief Legal Officer & Corporate Secretary | 3.7yrs | US$582.15k | 0.083% $ 94.2k | |
| Senior Vice President of Operations | 2.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
3.1yrs
Average Tenure
45yo
Average Age
Experienced Management: CNTX's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.9yrs | US$860.68k | 1.31% $ 1.5m | |
| Independent Chairman of the Board | 3.8yrs | US$105.17k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$76.33k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$79.83k | 0% $ 0 | |
| Independent Director | 6yrs | US$59.83k | 0.0047% $ 5.4k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
3.8yrs
Average Tenure
59yo
Average Age
Experienced Board: CNTX's board of directors are considered experienced (3.8 years average tenure).